Search Results

Use of GLP-1 Receptor Agonists for Weight Loss Leads to Shortages for Diabetes Patients

New paper highlights the need for integrated digital behavioral support, proposing a “habit window hypothesis” and associated research agenda to maximize the long-term success of GLP-1 therapies

The study will begin enrolling eligible patients in September. Thirty participants, ages 12 and older, will be randomized to receive either a placebo or the GLP-1 receptor agonist semaglutide

Medicare’s $50 GLP-1 discount excludes some patients with qualifying health conditions, leaving them facing higher costs

From long-term treatment and side effects to online safety and new uses, experts answer common questions about GLP-1 medications.

Integrating pharmacology, personalized nutrition, and precision medicine to improve management of obesity and type 2 diabetes.